Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes. Evidence to date / Cinti, F.; Moffa, S.; Impronta, F.; Cefalo, C. M. A.; Sun, V. A.; Sorice, G.; Mezza, T.; Giaccari, A.. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - 11:(2017), pp. 2905-2919. [10.2147/DDDT.S114932]

Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes. Evidence to date

Cefalo C. M. A.;
2017

Abstract

Sodium-glucose cotransporter 2 (SGLT2) inhibitors are the latest therapeutic strategy in the treatment of type 2 diabetes mellitus (T2DM). Using an insulin-independent mechanism (glycosuria), they reduce glucose toxicity and improve insulin sensitivity and β-cell function. The promising results obtained in clinical trials show that SGLT2 significantly improves glycemic control and provides greater cardiovascular protection, combined with a reduction in body weight and blood pressure (BP). This review focuses on ertugliflozin, a new, highly selective, and reversible SGLT2 inhibitor. Clinical trials published to date show that ertugliflozin, both as a monotherapy and as an add-on to oral antidiabetic agents, is safe and effective in reducing glycosylated hemoglobin (HbA1c), body weight, and BP in T2DM patients.
2017
antidiabetic drugs; glycemic control; glycosylated hemoglobin; precision medicine; sodium-glucose cotransporter 2 inhibitors; type 1 diabetes mellitus; type 2 diabetes mel­litus; weight reduction
01 Pubblicazione su rivista::01a Articolo in rivista
Spotlight on ertugliflozin and its potential in the treatment of type 2 diabetes. Evidence to date / Cinti, F.; Moffa, S.; Impronta, F.; Cefalo, C. M. A.; Sun, V. A.; Sorice, G.; Mezza, T.; Giaccari, A.. - In: DRUG DESIGN, DEVELOPMENT AND THERAPY. - ISSN 1177-8881. - 11:(2017), pp. 2905-2919. [10.2147/DDDT.S114932]
File allegati a questo prodotto
File Dimensione Formato  
Cinti_Spotlight-on ertugliflozin-and its-potential_2017.pdf

accesso aperto

Tipologia: Versione editoriale (versione pubblicata con il layout dell'editore)
Licenza: Creative commons
Dimensione 962.91 kB
Formato Adobe PDF
962.91 kB Adobe PDF

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/1675073
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 67
  • ???jsp.display-item.citation.isi??? 60
social impact